ANTICOAGULANT THERAPY OF VENOUS THROMBOEMBOLIC COMPLICATIONS: PROBLEMS AND PERSPECTIVES
https://doi.org/10.15829/1560-4071-2015-3-7-17
Abstract
The review takes into consideration the problems of effectiveness and safety of anticoagulant therapy in patients with venous thromboembolic complications. together with literature data we provide the results of our own study of optimization of long-term anticoagulant therapy in venous thromboembolic comlications. Particularly the results provided of comparison of standard therapy by high-molecular weight heparin (5 days or more) and warfarin and therapy by treatment dosages of enoxaparine with the prolonged treatment to one month in outpatient practice. Also the opportunities discussed for the usage of novel oral anticoagulants — dabigatran elexilate, rivaroxaban, apixaban — as for the treatment of acute thrombosis episode, as in long-term period. the detailed view is presented at the defining of optimal duration of anticoagulant therapy and the factor influencing the effectiveness and safety of long-term treatment. As the latter we recommend to use laboratory markers: d-dimer and thrombin-activating fibrinolysis inhibitor.
About the Authors
N. M. Vorobieva
FSBI Russian Cardiological scientific-Production Complex of the healthcare Ministry, Moscow, Russia
Russian Federation
Russian Federation
E. P. Panchenko
FSBI Russian Cardiological scientific-Production Complex of the healthcare Ministry, Moscow, Russia
Russian Federation
Russian Federation
References
1. Spencer FA, Emery C, Lessard d, et al. the Worcester Venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J gen Intern Med 2006; 21: 722-7.
2. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VtE disease: Antithrombotic therapy and Prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice guidelines. Chest 2012; 141 (suppl): e419s-e494s.
3. Hylek EM, Regan s, henault LE, et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 2003; 163: 621-7.
4. Hull Rd, Raskob gE, Brant RF, et al. Relation between the time to achieve the lower limit of the APtt therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157: 2562-8.
5. 2014 EsC guidelines on the diagnosis and management of acute pulmonary embolism. the task Force for the diagnosis and Management of Acute Pulmonary Embolism of the European society of Cardiology (EsC). Eur heart J 2014; 35: 3033-80.
6. Russian clinical guidelines on the diagnosis, treatment and prophylaxis of venous thromboembolic complications. Phlebology 2010; 4 (1): 4-37. Russian (Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. флебология 2010; 4 (1): 4-37).
7. Vorobyeva nM. Optimization of long-term anticoagulant therapy in deep vein thrombosis and pulmonary embolism. Avtoref. dis. doct. med. nauk. M., 2013: 42 str. Russian (Воробьёва Н. М. Оптимизация длительной антикоагулянтной терапии при тромбозах глубоких вен и тромбоэмболии лёгочной артерии. Автореф. дис. докт. мед. наук. М., 2013: 42 с).
8. Lee Ay, Levine Mn, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for prevention of recurrent venous thromboembolism in patient with cancer. n Engl J Med 2003; 349: 146-53.
9. hull Rd, Pineo gF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-72.
10. Meyer g, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-35.
11. Vorobyeva nM, Panchenko EP, Kirienko AI, et al. Warfarin or enoxaparin: what to appoint to the patient with venous thrombosis in the first month of treatment? terapevticheskiy archiv 2009; 81 (9): 57-61. Russian (Воробьёва Н. М., Панченко Е. П., Кириенко А. и. и др. Варфарин или эноксапарин: что назначить больному венозным тромбозом в первый месяц лечения? Терапевтический архив 2009; 81 (9): 57-61).
12. Vorobyeva nM, Panchenko EP, Ermolina OV, et al. Extension of enoxaparin therapy until one month promotes the recanalization of occlusive thrombosed deep veins. terapevticheskiy archiv 2011; 83 (8): 33-7. Russian (Воробьёва Н. М., Панченко Е. П., Ермолина О. В. и др. Продление терапии эноксапарином до одного месяца способствует реканализации окклюзивно тромбированных глубоких вен. Терапевтический архив 2011; 83 (8): 33-7).
13. Vorobyeva nM, Panchenko EP, dobrovolsky AB, et al. Improvement of the recanalization of deep veins and “outcomes” of venous thromboembolic complications at the prolonged enoxaparin therapy. Angiology and vascular surgery 2011: 17 (1): 87-94. Russian (Воробьёва Н. М., Панченко Е. П., добровольский А. б. и др. Улучшение реканализации глубоких вен и “исходы” венозных тромбоэмболических осложнений при продлённой терапии эноксапарином. Ангиология и сосудистая хирургия 2011; 17 (1): 87-94).
14. Vorobyeva n, Panchenko E, Ermolina O, et al. Prolongation of enoxaparin therapy to one month improves recanalization of occlusive thrombosed deep veins. thrombosis Research 2014; 133 (suppl. 3):s66.
15. Vorobyeva nM, dobrovolsky AB, titaeva EV, et al. Practical aspects of extension of enoxaparin therapy until one month in out-patient conditions in patients with venous thromboembolic complications. Aterotromboz 2014; 1: 33-43. Russian (Воробьёва Н. М., добровольский А. Б., Титаева Е. В. и др. Практические аспекты продления терапии эноксапарином до одного месяца в амбулаторных условиях у больных венозными тромбоэмболическими осложнениями. Атеротромбоз 2014; 1: 33-43).
16. Antithrombotic therapy in patients with stable manifestations of atherothrombosis. national clinical guidelines of VnOK. Cardiovascular therapy and Prevention 2009; 8 (6): Appendix 6. Russian (Антитромботическая терапия у больных со стабильными проявлениями атеротромбоза. Национальные клинические рекомендации ВНОк. кардиоваскулярная терапия и профилактика 2009; 8 (6): Приложение 6).
17. schulman s, Kearon C, Kakkar AK, et al. dabigatran versus warfarin in the treatment of acute venous thromboembolism. n Engl J Med 2009; 361: 2342-52.
18. the EInstEIn Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. n Engl J Med 2010; 363: 2499-510.
19. the EInstEIn-PE Investigators. Oral Rivaroxaban for the treatment of symptomatic Pulmonary Embolism. n Engl J Med 2012; 366: 1287-97.
20. Agnelli g, Buller hR, Cohen A, et al. AMPLIFy Investigators. Oral Apixaban for the treatment of Acute Venous thromboembolism. n Engl J Med 2013; 369: 799-808.
21. Vorobyeva nM, Panchenko EP. new oral anticoagulants and acetylsalicylic acid in the treatment of venous thromboembolic complications. Aterotromboz 2013; 1: 53-64. Russian (Воробьёва Н. М., Панченко Е. П. Новые пероральные антикоагулянты и аце-тилсалициловая кислота в лечении венозных тромбоэмболических осложнений. Атеротромбоз 2013; 1: 53-64).
22. Vorobyeva nM, Panchenko EP. dabigatran etexilate — new oral anticoagulant for the treatment of venous thromboembolic complications. Aterotromboz 2014; 1: 50-8. Russian (Воробьёва Н. М., Панченко Е. П. дабигатрана этексилат — новый перо-ральный антикоагулянт для лечения венозных тромбоэмболических осложнений. Атеротромбоз 2014; 1: 50-8).
23. Vorobyeva nM. Features of rivaroxaban application in patients with venous thromboembolic complications. Meditsinskiy alfavit 2014; 3 (219): 28-34. Russian (Воробьёва Н. М. Особенности применения ривароксабана у больных венозны-ми тромбоэмболическими осложнениями. Медицинский алфавит 2014; 3 (219): 28-34).
24. Vorobyeva nM, Panchenko EP. Efficacy and safety of long-term dabigatran therapy at atrial fibrillation. Aterotromboz 2014; 2: 2-10. Russian (Воробьёва Н. М., Панченко Е. П. эффективность и безопасность длительной терапии дабигатраном при фибрилляции предсердий. Атеротромбоз 2014; 2: 2-10).
25. Vorobyeva nM, Panchenko EP, dobrovolsky AB, et al. Polymorphisms of CyP2C9 and VKORC1 genes in patients with venous thromboembolic complications in the Moscow population: influence on stability of anticoagulant therapy and frequency of bleedings. terapevticheskiy archiv 2011; 83 (6): 59-66. Russian (Воробьёва Н. М., Панченко Е. П., добровольский А. б. и др. Полиморфизмы генов СYР2С9 и VКОRС1 у больных с венозными тромбоэмболическими осложнениями в московской популяции: влияние на стабильность антикоагулянтной терапии и частоту кровотечений. Терапевтический архив 2011; 83 (6): 59-66).
26. van tilburg nh, Rosendaal FR, Bertina RM. thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
27. Eichinger s, schonauer V, Weltermann A, et al. thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103: 3773-6.
28. Vorobyeva nM, dobrovolsky AB, titaeva EV, et al. Low level of the thrombin activatable fibrinolysis inhibitor increases the risk of bleedings during long-term warfarin therapy. Lechschiy vrach 2014; 2: 15-20. Russian (Воробьёва Н. М., добровольский А. б., Титаева Е. В. и др. Низкий уровень активируемого тромбином ингибитора фибринолиза увеличивает риск кровотечений в период длительной терапии варфарином. Лечащий врач 2014; 2: 15-20).
29. Vorobyeva nM, dobrovolsky AB, titaeva EV, et al. Low tAFI levels increase the risk of hemorrhagic complications during long-term warfarin therapy. Eur heart J 2012; 33 (Abstract suppl.):342.
30. Wu C, Bates sM. should d-dimer testing be used to predict the risk of recurrence after discontinuation of anticoagulant therapy for a first unprovoked episode of venous thromboembolism? Pol Arch Med Wewn 2009; 119: 225-30.
31. Palareti g, Legnani C, Cosmi B, et al. Risk of venous thromboembolism recurrence: high negative predictive value of d-dimer performed after oral anticoagulation is stopped. thromb haemost 2002; 87: 7-12.
32. Eichinger s, Minar E, Bialonczyk C, et al. d-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290: 1071-4.
33. Palareti g., Legnani C., Cosmi B. et al. Predictive value of d-dimer testing for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-8.
34. Palareti g, Cosmi B, Legnani C, et al. for the PROLOng Investigators. d-dimer testing to determine the duration of anticoagulant therapy. n Engl J Med 2006; 355: 1780-9.
35. Vorobyeva nM, Panchenko EP, dobrovolsky AB, et al. Independent predictors of recurrence of deep vein thrombosis (results of prospective 18-months observation). Cardiology 2010; 50 (12): 52-8. Russian (Воробьёва Н. М., Панченко Е. П., Добровольский А. б. и др. Независимые предикторы рецидива тромбоза глубоких вен (результаты проспективного 18-месячного наблюдения). кардиология 2010; 50 (12): 52-8).
36. Vorobyeva nM, dobrovolsky AB, titaeva EV, et al. d-dimer testing during anticoagulant therapy should be used to indicate patients who need extended anticoagulant therapy. Eur heart J 2013; 34 (suppl. 1): 189.
37. Schulman s, Rhedin A-s, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. n Engl J Med 1995; 332: 1661-5.
38. Agnelli g, Prandoni P, santamaria Mg, et al. three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. n Engl J Med 2001; 345: 165-9.
39. Agnelli g, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139: 19-25.
40. Agnelli g, Buller hR, Cohen A, et al. for the AMPLIFy-Ext Investigators. Apixaban for Extended treatment of Venous thromboembolism. n Engl J Med 2013; 368: 699-708.
41. Becattini C, Agnelli g, schenone A, et al. Aspirin for Preventing the Recurrence of Venous thromboembolism. n Engl J Med 2012; 366: 1959-67.
42. Brighton tA, Eikelboom JW, Mann K, et al. Low-dose Aspirin for Prevention Recurrent Venous thromboembolism. n Engl J Med 2012; 367:1979-87.
Review
For citations:
Vorobieva N.M., Panchenko E.P. ANTICOAGULANT THERAPY OF VENOUS THROMBOEMBOLIC COMPLICATIONS: PROBLEMS AND PERSPECTIVES. Russian Journal of Cardiology. 2015;(3):7-17. (In Russ.) https://doi.org/10.15829/1560-4071-2015-3-7-17
Views:
965
Email this article 